Sanofi-aventis embarks upon major anti-malaria study
23 November 2009 00:00 in Pharmaceutical Company Product News
Sanofi-aventis has forged a partnership with Medicines for Malaria, which will see the two organisations collaborate to launch the largest study into the effects of an antimalarial drug.
The firms will work to evaluate the safety of a fixed-dose combination of artesunate and amodiaquine, entitled ASAQ.
It is the only fixed-dose combination of these therapies that has been approved by the World Health Organization for the treatment of Plasmodium falciparum uncomplicated malaria.
Robert Sebbag, vice-president of Sanofi-aventis' Access to Medicines programme, commented: "We have designed an innovative field-monitoring program to assess the effectiveness and safety of ASAQ in real-life conditions."
Mr Sebbag continued by describing the trial as the "the most ambitious drug monitoring programme ever to be launched in Africa".
In other Sanofi-aventis news, the firm revealed last week that it plans to collaborate with Regeneron to expand their joint portfolio of antibody products.
Other news stories from 23/11/2009
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency